Nxera Pharma Co Ltd (SOLTF)
9.816
+0.04
(+0.37%)
USD |
OTCM |
May 10, 16:00
Nxera Pharma Enterprise Value: 1.018B for May 10, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 10, 2024 | 1.018B |
| May 09, 2024 | 1.014B |
| May 08, 2024 | 993.79M |
| May 07, 2024 | 993.79M |
| May 06, 2024 | 993.79M |
| May 03, 2024 | 993.79M |
| May 02, 2024 | 971.78M |
| May 01, 2024 | 971.78M |
| April 30, 2024 | 971.78M |
| April 29, 2024 | 971.43M |
| April 26, 2024 | 971.43M |
| April 25, 2024 | 1.009B |
| April 24, 2024 | 1.009B |
| April 23, 2024 | 1.009B |
| April 22, 2024 | 1.009B |
| April 19, 2024 | 1.009B |
| April 18, 2024 | 1.009B |
| April 17, 2024 | 1.009B |
| April 16, 2024 | 1.009B |
| April 15, 2024 | 1.073B |
| April 12, 2024 | 1.073B |
| April 11, 2024 | 1.073B |
| April 10, 2024 | 1.073B |
| April 09, 2024 | 1.073B |
| April 08, 2024 | 1.073B |
| Date | Value |
|---|---|
| April 05, 2024 | 1.033B |
| April 04, 2024 | 1.033B |
| April 03, 2024 | 1.033B |
| April 02, 2024 | 1.106B |
| April 01, 2024 | 1.106B |
| March 31, 2024 | 1.081B |
| March 28, 2024 | 1.082B |
| March 27, 2024 | 1.082B |
| March 26, 2024 | 1.082B |
| March 25, 2024 | 1.082B |
| March 22, 2024 | 1.082B |
| March 21, 2024 | 1.082B |
| March 20, 2024 | 1.082B |
| March 19, 2024 | 1.082B |
| March 18, 2024 | 1.082B |
| March 15, 2024 | 1.101B |
| March 14, 2024 | 1.101B |
| March 13, 2024 | 1.101B |
| March 12, 2024 | 1.341B |
| March 11, 2024 | 1.341B |
| March 08, 2024 | 1.024B |
| March 07, 2024 | 1.024B |
| March 06, 2024 | 1.024B |
| March 05, 2024 | 1.024B |
| March 04, 2024 | 1.024B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
429.47M
Minimum
May 12 2022
1.713B
Maximum
Jul 29 2019
1.016B
Average
1.009B
Median
Apr 16 2024
Enterprise Value Benchmarks
| Takeda Pharmaceutical Co Ltd | 70.46B |
| PeptiDream Inc | 1.685B |
| Healios KK | 73.17M |
| AnGes Inc | 37.97M |
| SanBio Co Ltd | 238.51M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -22.11M |
| Revenue (Quarterly) | 31.07M |
| Total Expenses (Quarterly) | 51.79M |
| EPS Diluted (Quarterly) | -0.2471 |
| Gross Profit Margin (Quarterly) | 74.17% |
| Profit Margin (Quarterly) | -71.16% |
| Earnings Yield | -7.48% |
| Normalized Earnings Yield | -7.479 |